BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Product Information

Indications1

BRILIQUE (ticagrelor), co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with:

  • acute coronary syndromes (ACS)
  • a history of myocardial infarction (MI) and a high risk* of developing an atherothrombotic event

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with ASA to protect post-MI patients at high risk of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings.1,2,3

 

* High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg  twice daily  in combination with ASA is indicated for patients with ACS for up to 12 months. BRILIQUE (ticagrelor) 90mg twise daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

BRILIQUE (ticagrelor) 90mg use in acute coronary syndrome1

BRILIQUE (ticagrelor) 90mg treatment should be initiated with a single 180mg loading dose and then continued at 90mg twice daily.

Treatment with BRILIQUE (ticagrelor) 90mg twice daily is recommended for 12 months in ACS patients unless discontinuation is clinically indicated.

BRILIQUE (ticagrelor) 60mg after an MI in those at high-risk*1

BRILIQUE (ticagrelor) 60mg  twice daily is the recommended dose when an extended treatment is required for patients with a history of MI of ≥1 year and high risk* of an atherothrombotic event.

Treatment may be started without interruption as continuation therapy after the initial one year treatment with BRILIQUE (ticagrelor) 90mg (or other adenosine diphosphate (ADP) receptor inhibitor therapy) in MI patients with a high risk* of an atherothrombotic event. Treatment can also be initiated up to 2 years from the MI, or within one year after stopping previous ADP receptor inhibitor treatment.

There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment.

If a switch is needed, the first dose of BRILIQUE (ticagrelor) should be administered 24 hours following the last dose of the other antiplatelet medication.

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor approved in both long- and short-term settings1

Study design overviews for PLATO and PEGASUS-TIMI 54
Study design overviews for PLATO and PEGASUS-TIMI 54